Lo Minastrin Fe is an oral contraceptive owned by Apil. The drug, which provides pregnancy prevention, was first authorized for market use on July 24, 2013. It contains Ethinyl Estradiol and Norethindrone Acetate as active ingredients.
The generic version of Lo Minastrin Fe is not yet available. The last patent held on this drug will expire on February 2, 2029, opening up the possibility for generic versions to be released.
Lo Minastrin Fe is primarily used for the prevention of pregnancy. Its efficacy is largely due to its active ingredients, Ethinyl Estradiol and Norethindrone Acetate, which work together to inhibit ovulation.
Lo Minastrin Fe holds a total of 1 drug patent, none of which have yet expired. The last patent, titled 'Extended estrogen dosing contraceptive regimen', is set to expire on February 2, 2029. Below are the details of the patent: